177755-45-2

Upstream product

• 7677-24-9 trimethylsilyl cyanide 
• 351-54-2 3-fluoro-p-anisaldehyde 

Downstream Products

• 66985-46-4 (+/-)-2-(4-chlorophenyl)-2-(trimethylsiloxy)-acetonitrile 
• 177755-69-0 3,4-difluoro-α-[(trimethylsilyl)oxy]benzeneacetonitrile 
• 94010-80-7 2,4-difluoro-α-[(trimethylsilyl)oxy]benzeneacetonitrile 
• 66985-47-5 2-chloro-α-[(trimethylsilyl)oxy]benzeneacetonitrile 
• 177755-46-3 1-(3-fluoro-4-methoxyphenyl)-2-hydroxy-2-[4-(methylthio)phenyl]ethanone 
• 95392-03-3 2-(3,4-dichlorophenyl)-2-((trimethylsilyl)oxy)acetonitrile 
• 66985-48-6 2-(4-methoxyphenyl)-2-(trimethylsilyloxy)acetonitrile 
• 66985-49-7 2-(4-methylphenyl)-2-(trimethylsilyloxy)acetonitrile 
• 177755-50-9 1-(4-chlorophenyl)-2-[4-(methylthio)phenyl]ethane-1,2-dione 
• 177755-52-1 1-(2-chlorophenyl)-2-hydroxy-2-[4-(methylthio)phenyl]ethanone 
• 177755-49-6 1-(4-chlorophenyl)-2-hydroxy-2-[4-(methylthio)phenyl]ethanone 
• 177755-47-4 1-(3-fluoro-4-methoxyphenyl)-2-[4-(methylthio)phenyl]ethane-1,2-dione 
• 177755-54-3 5-(2-chlorophenyl)-4-[4-(methylthio)phenyl]-2-(trifluoromethyl)-1H-imidazole 
• 177755-51-0 5-(4-chlorophenyl)-4-[4-(methylthio)phenyl]-2-(trifluoromethyl)-1H-imidazole 

Relevant academic research and scientific papers

Substituted hydantoins

The present invention relates to compounds of the formula which are useful in treating diseases characterized by the hyperactivity of MEK. Accordingly the compounds are useful in the treatment of diseases, such as, cancer, cognative and CNS disorders and inflammatory/autoimmune diseases.

Phosphonic acids derivatives as inhibitors of protein tyrosine phosphate 1B (PTP-1B)

The invention encompasses the novel class of compounds represented by formula I which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases.

Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation

A class of imidazolyl compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula II STR1 wherein R1 is selected from lower alkyl, lower haloalkyl, lower hydroxyalkyl, lower aralkenyl, lower aryloxyalkyl, lower arylthioalkyl and heteroaryl; wherein R3 is selected from lower alkyl and amino; and wherein R4 is one or more radicals selected from hydrido, halo, lower alkyl and lower alkoxy; or where R4 together with the phenyl radical forms naphthyl or benzodioxolyl; provided R1 is not lower alkyl when R3 is methyl and when R4 is hydrido, methyl, methoxy or chloro; or a pharmaceutically-acceptable salt thereof.